Royce & Associates’s Cytokinetics CYTK Stock Holding History

Royce & Associates’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.66M	Sell	101,624 -22,673	-18%	-$1.63M	0.07%	407
2026 Q1	$8.19M	Sell	124,297 -20,129	-14%	-$1.28M	0.08%	384
2025 Q4	$9.18M	Buy	144,426 +44,343	+44%	+$2.76M	0.09%	334
2025 Q3	$5.5M	Buy	+100,083	New	+$4.12M	0.05%	449
2024 Q4	–	Sell	-24,250	Closed	-$1.28M	–	852
2024 Q3	$1.28M	Buy	24,250 +10,000	+70%	+$557K	0.01%	694
2024 Q2	$772K	Hold	14,250	–	–	0.01%	751
2024 Q1	$999K	Buy	+14,250	New	+$1.1M	0.01%	725
2014 Q2	–	Sell	-700,000	Closed	-$6.65M	–	1426
2014 Q1	$6.65M	Buy	+700,000	New	+$6.33M	0.02%	802

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's CYTK Position: Q2 2026 in Review

Royce & Associates reduced its Cytokinetics (CYTK) stake by 18% in Q2 2026, selling an estimated $1.63M and leaving 101,624 shares worth $8.66M. The position accounts for 0.07% of the portfolio, ranked #407.

Royce & Associates first reported a position in CYTK in Q1 2014 and has held it in 8 quarters since. The position peaked at $9.18M in Q4 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Royce & Associates held 101,624 shares of Cytokinetics worth $8.66M as of Q2 2026.
Royce & Associates sold 22,673 Cytokinetics shares in Q2 2026, an estimated $1.63M.
Cytokinetics made up 0.07% of Royce & Associates's portfolio in Q2 2026, its #407 holding.
Royce & Associates first reported a position in Cytokinetics in Q1 2014 and has held it in 8 quarters since.
Royce & Associates's Cytokinetics position peaked at $9.18M in Q4 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.